and FEV 1 AUC 12-24 were significantly increased from baseline with aclidinium (Δ = 150 mL and 160 mL, respectively; p < 0.0001) and tiotropium (Δ = 140 mL and 123 mL, respectively; p < 0.0001) at week 6. Significant improvements in E-RS total scores over 6 weeks were numerically greater with aclidinium (p < 0.0001) than tiotropium (p < 0.05) versus placebo. Only aclidinium significantly reduced the severity of early-morning cough, wheeze, shortness of breath, and phlegm, and of nighttime symptoms versus placebo (p < 0.05). Adverse-event (AE) incidence (28%) was similar between treatments. Few anticholinergic AEs (<1.5%) or serious AEs (<3%) occurred in any group. Conclusions: Aclidinium provided significant 24-hour bronchodilation versus placebo from day 1 with comparable efficacy to tiotropium after 6 weeks. Improvements in COPD symptoms were consistently numerically greater with aclidinium versus tiotropium. Aclidinium was generally well tolerated.
Introduction Beier et al.
and symptoms has been better characterized, the clinical relevance of nighttime symptoms can sometimes be underestimated in COPD and a lack of routine assessment means they can be under-reported (6) . As symptoms throughout the day impact on patient quality of life (5) , maintaining signifi cant bronchodilation and symptom control over 24 hours should be an important goal of therapy.
Inhaled bronchodilatory therapies, including longacting β 2 -agonists and long-acting muscarinic antagonists (LAMAs), are central to COPD management (7); however, until recently, tiotropium bromide was the only available agent in the LAMA class (2, 8) . Aclidinium bromide is a LAMA that has recently been approved as a maintenance bronchodilator treatment for patients with COPD (9, 10). In a Phase IIa study, twice-daily (BID) treatment with aclidinium 400 μg was demonstrated to provide signifi cant improvements in 24-hour bronchodilation versus placebo that were generally similar to once-daily (QD) treatment with tiotropium 18 μg after 2 weeks, although signifi cant diff erences in favor of aclidinium were observed for the nighttime period (11) .
Th e Phase IIIb study reported in this paper was conducted to confi rm the 24-hour bronchodilatory effi cacy of aclidinium versus placebo and tiotropium over a longer treatment period (6 weeks) and in a larger population. Th e eff ects of treatment on COPD symptoms, inhaler preference, and safety were also evaluated in this Phase IIIb study.
Methods

Study design and treatment
Th is randomized, double-blind, double-dummy, placebo-and active comparator-controlled, multicenter Phase IIIb study was conducted in the Czech Republic, Germany, Hungary, and Poland between October 2011 and March 2012 (clinicaltrials.gov identifi er NCT01462929).
Following screening and a 2-to 3-week run-in period, during which disease stability was assessed, patients were randomized (2:2:1) via an interactive voice-response system and computer-generated schedule to receive aclidinium bromide 400 μg (metered dose; equivalent to aclidinium 322 μg delivered dose) BID in the morning and evening via the Genuair ® /Pressair TM multidose dry powder inhaler, tiotropium 18 μg QD in the morning via the HandiHaler ® , or placebo for 6 weeks. Two Genuair inhalers (pre-loaded with 1 month's supply [60 doses] of either aclidinium or matched placebo) and one HandiHaler (with 60 capsules of tiotropium or matched placebo) were supplied. To maintain blinding, patients were instructed to use both inhalers each morning (9:00 ± 1 hour) and Genuair only each evening (21:00 ± 1 hour). Patients and study personnel remained blinded to treatment allocation throughout the study. Training on the correct use of the inhalers was provided at screening and before randomization on day 1.
Relief medication (salbutamol pressurized metereddose inhaler 100 μg/puff ) was provided for additional symptom control as needed (except ≤6 hours before each visit). Patients were permitted to continue stable use of oral sustained-release theophylline (use of other methylxanthines was not permitted), inhaled corticosteroids, and oral or parenteral corticosteroids (prednisone ≤10 mg/day or 20 mg/every other day, or equivalent), except ≤6 hours before each visit. Oxygen therapy (except ≤2 hours before each visit) was allowed.
Th e study was approved by an independent ethics committee at each site and was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization and Good Clinical Practice. Patients provided written informed consent before participating in any study procedures.
Patients
Eligible patients were aged ≥40 years with a clinical diagnosis of stable moderate-to-severe COPD (postbronchodilator forced expiratory volume in 1 second [FEV 1 ]/forced vital capacity [FVC] <70%, and FEV 1 ≥30% and <80%) (12) and were either current or former cigarette smokers (smoking history of ≥10 pack-years). Patients with a history or current diagnosis of asthma or other clinically signifi cant respiratory or cardiovascular conditions were excluded, as were those who had experienced any respiratory tract infection or COPD exacerbation ≤6 weeks before screening (≤3 months if exacerbation resulted in hospitalization), or for whom the use of muscarinic antagonists was contraindicated. Additional relevant exclusion criteria included hypersensitivity to inhaled muscarinic antagonists and inability to use the study inhalers properly.
Patients could be discontinued from the study at any time at their own request or in the event of ineligibility, non-compliance, lack of effi cacy, loss to follow-up, safety concerns (including moderate or severe COPD exacerbation), or any other reason at the investigator's discretion.
Study Assessments
Lung function
Lung function was assessed over 24 hours following morning treatment on day 1 and at week 6. FEV 1 and FVC were measured using procedures and spirometers that met European Respiratory Society (ERS) and American Th oracic Society (ATS) standards (13) . Th ree manoeuvres were performed at each time point to provide three measurements that met ATS/ERS acceptability and repeatability criteria. Additional measurements could be made (up to a total of eight tests) if the fi rst three were not acceptable.
Th e primary endpoint was change from baseline in normalized FEV 1 area under the curve over the 24-hour period post-morning dose (AUC 0-24 ) at week 6 (tiotropium administered QD in the morning; aclidinium administered BID in the morning and evening). (14) total score (range 0-40; a higher score indicates more severe symptoms). An additional COPD symptoms questionnaire (developed by the study sponsor) was completed by patients each morning via electronic diaries to capture the severity of early-morning and nighttime symptoms (5-point scale: 1 = 'did not experience symptoms'; 5 = 'very severe'), and individual morning symptoms of cough, wheeze, shortness of breath, and phlegm (5-point scale: 0 = 'no symptoms'; 4 = 'very severe symptoms'), as well as limitation of morning activities (5-point scale: 1 = 'not at all'; 5 = 'a very good deal') and frequency of nocturnal awakenings as a result of COPD symptoms. Relief medication use was also recorded daily via electronic diaries.
Inhaler preference and willingness to continue After 6 weeks, overall inhaler preference and preference based on a number of specifi c inhaler attributes were assessed. Patients were fi rst asked "which inhaler do you prefer?" (Genuair, HandiHaler, or no preference) then, "which device do you prefer in terms of the following attributes: ease of use, convenience, ease of learning to use, ease of holding, ease of operating, ease of preparation of the dose, and feedback to indicate correct inhalation?" Willingness to continue using each inhaler was also rated on a scale from 0 = 'not willing' to 100 = 'definitely willing' .
Safety
Adverse events (AEs) were recorded throughout the study and assessed for severity and relationship to study treatment by the investigator. Other safety assessments included a physical examination and vital signs measurement at screening and week 6.
Statistical Analysis
A target population of approximately 405 patients was planned to provide a sample size of 385 patients, taking into account a 5% dropout rate. Th is provided >90% power to detect a 130 mL diff erence between aclidinium and placebo for the primary and secondary endpoints, and >80% power to detect a 70 mL diff erence between aclidinium and tiotropium for the secondary endpoint, with a two-sided signifi cance level of p < 0.05. Assumptions about treatment group diff erences were made based on observations from the previous Phase IIa study that compared the 24-hour bronchodilatory effi cacy of aclidinium with placebo and tiotropium (11) .
Effi cacy analyses were based on the intent-to-treat population, which included all treated patients (≥1 dose) who had ≥1 baseline and post-baseline FEV 1 value. Endpoints were assessed using an analysis of covariance model with treatment and sex as factors, and age and baseline values as covariates. Between-group least squares mean diff erences and 95% confi dence intervals were calculated for all treatment-group comparisons. Th e primary and secondary endpoint analyses were conducted in a stepwise manner to control for multiplicity: for FEV 1 AUC 0-24 , the primary comparison was aclidinium versus placebo; for FEV 1 AUC 12-24 , the primary comparison was aclidinium versus placebo, and the secondary comparison was aclidinium versus tiotropium. Other comparisons were considered additional.
Inhaler preference was summarized descriptively and the percentage of patients preferring Genuair was assessed using an exact binomial test. Willingness to continue inhaler use was assessed using an analysis of variance. Safety analyses included all treated patients (safety population) and were descriptive in nature.
Results
Patients
Of 485 patients screened, 414 patients from 41 sites (2.7% from 3 sites in the Czech Republic, 49.5% from 20 sites in Germany, 10.6% from 5 sites in Hungary, and 37.2% from 13 sites in Poland) were randomized, treated, and included in the study analyses, and 400 completed the study ( Figure 1 ). Th e discontinuation rate was slightly higher in the placebo group (5.9%) compared with the aclidinium (2.9%) or tiotropium (2.5%) groups. In the placebo group, reasons for discontinuation were AEs and lack of effi cacy, whereas in the aclidinium and tiotropium groups, reasons for discontinuation were AEs and patient's personal request ( Figure 1 ). No patients were lost to follow-up. Treatment compliance, as assessed by the investigator based on information provided in patients' electronic diaries and the Genuair dose indicator or number of tiotropium pierced capsules, was 94.1%, 98.2%, and 96.8% in the placebo, aclidinium, and tiotropium groups, respectively.
Demographics and baseline characteristics were similar across treatment groups, with the exception of higher proportions of male patients in the aclidinium and tiotropium groups than in the placebo group (Table 1) . Mean post-bronchodilator percent predicted FEV 1 at screening (adjusted for gender-related diff erences) was similar in each treatment group but, refl ective of the higher proportion of male patients in the active treatment groups, mean FEV 1 was slightly higher in these groups versus the placebo group. In total, 86.7% of patients had used COPD medications prior to the start of the study. Anticholinergic therapies (LAMA, short-acting muscarinic antagonist [SAMA], or short-acting β-2 agonist plus SAMA) had been used by 25.6%, 18.8%, and 5.3% of patients, respectively. In the primary endpoint analysis, FEV 1 AUC 0-24 was signifi cantly improved with aclidinium compared with placebo at week 6 (p < 0.0001; Figure 2B ). Compared with placebo, tiotropium also signifi cantly increased FEV 1 AUC 0-24 from baseline to week 6 (p < 0.0001; Figure 2B) ; the eff ects of aclidinium and tiotropium over 6 weeks were similar.
Over 6 weeks, FEV 1 AUC 12-24 and FEV 1 AUC 0-12 were also signifi cantly increased from baseline with both aclidinium and tiotropium versus placebo (p < 0.0001) ( Figure 2B ). Although the improvement in FEV 1 AUC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] was numerically greater with aclidinium versus tiotropium, and the improvement in FEV 1 AUC 0-12 was numerically greater with tiotropium versus aclidinium, there were no signifi cant diff erences between active treatments (p = 0.12 and p = 0.48, respectively).
Both aclidinium and tiotropium produced signifi cant increases from baseline in FEV 1 versus placebo at each observation time point from 15 minutes to 24 hours postdose on day 1 and at week 6 ( Figure 3 ). Both aclidinium and tiotropium also signifi cantly improved morning pre-dose (trough) and peak FEV 1 and FVC compared with placebo on day 1 and at week 6 ( Table 2) . Improvements were numerically greater with aclidinium versus tiotropium, with signifi cant diff erences in favor of aclidinium for trough FEV 1 and FVC on day 1.
COPD Symptoms and Relief Medication Use
Over 6 weeks, E-RS total scores were signifi cantly reduced from baseline with both aclidinium (p < 0.0001) and tiotropium (p < 0.05) versus placebo ( Figure 4 ). Improvements in individual domain scores were numerically greater with aclidinium than tiotropium, and the improvement for cough and sputum was signifi cant versus placebo for aclidinium only (p < 0.05). Comparisons of aclidinium versus tiotropium yielded no signifi cant diff erences.
Th e severity of early-morning symptoms, overall, was signifi cantly reduced over 6 weeks with aclidinium (p < 0.001) and tiotropium (p < 0.05) versus placebo (Figure 5A) ; the diff erence between active treatments was not statistically signifi cant. Only aclidinium produced signifi cant improvements in individual early-morning symptoms of phlegm, shortness of breath, wheeze, and cough compared with placebo at week 6. Nighttime symptom severity was signifi cantly reduced from baseline over 6 weeks with aclidinium versus placebo but not with tiotropium versus placebo ( Figure 5B) ; the diff erence between active treatments was not statistically signifi cant. Th ere were no signifi cant changes from baseline in number of nocturnal awakenings in any treatment group. Limitation of activity caused by COPD symptoms was also signifi cantly reduced from baseline over 6 weeks with aclidinium versus placebo but not with tiotropium versus placebo ( Figure 5 ). Th is improvement in limitation of activity was signifi cantly greater for aclidinium versus tiotropium (p < 0.05). Over 6 weeks, there was a signifi cant increase in relief medication-free days with aclidinium and tiotropium versus placebo (diff erence of 9.6% and 8.9%, respectively; p < 0.05).
Inhaler preference
When asked "which device do you prefer?" at week 6, signifi cantly more patients overall preferred Genuair to HandiHaler (80.1% vs 10.7%; p < 0.0001). Th e option of 'no preference' was chosen by 9.2% of patients. Additionally, >75% of patients preferred Genuair to HandiHaler for each of the individual inhaler attributes assessed (Table 3) . Inhaler preference appeared to be independent of whether active medication or placebo was administered via the inhalers: when the aclidinium, tiotropium, and placebo groups were analyzed separately, ≥79% of patients preferred Genuair compared with ≤13% who preferred HandiHaler in each group. Patients were more willing to continue using Genuair than HandiHaler, as indicated by a signifi cant diff erence in mean ratings at week 6 (88.8 vs 45.4; p < 0.0001).
Safety
AE incidence was similar in the placebo (25.9%), aclidinium (27.5%), and tiotropium (29.7%) groups. Nasopharyngitis and headache were most common, each reported by 5.1% of patients overall. Nasopharyngitis occurred more frequently with aclidinium and tiotropium versus placebo (5.8% and 5.7% vs 2.4%, respectively); headache occurred more frequently with aclidinium than with either placebo or tiotropium (7.0% vs 3.5% and 3.8%, respectively). Other common AEs (≥2% of patients overall) were COPD exacerbation (2.4%) and cough (2.2%). Th e majority of AEs were mild or moderate in intensity. Th ere were few serious AEs (1.7% overall) and no deaths. In total, 8 patients (1.9%) discontinued due to AEs, with COPD exacerbation being the most common cause (n = 2 in each treatment group). No AEs resulting in discontinuation were considered to be treatment-related.
With the exception of dry mouth, which was reported by three patients (0.7%) in total (aclidinium n = 1; tiotropium n = 2), no other treatment-related AEs occurred in >1 patient overall. Th e incidence of potentially anticholinergic AEs was similarly low across treatment groups (<1.5% in any group). Only dry mouth, pharyngitis (placebo n = 1; aclidinium n = 1; tiotropium n = 2), and constipation (tiotropium n = 2) occurred in >1 patient in any group. No potentially anticholinergic AEs were serious or led to discontinuation. Th ere were no clinically signifi cant physical examination or vital signs fi ndings.
Discussion
Th is Phase IIIb study was designed to evaluate the 24-hour bronchodilatory effi cacy of aclidinium 400 μg BID in patients with moderate-to-severe COPD. Findings from our primary endpoint analysis of change from baseline in FEV 1 AUC 0-24 after 6 weeks of treatment www.copdjournal.com demonstrated a statistically signifi cant improvement with aclidinium versus placebo, and changes from baseline in trough FEV 1 with aclidinium exceeded the proposed minimally important diff erence for this parameter (100-140 mL) (15, 16) . Furthermore, aclidinium significantly improved day time and nighttime bronchodilation over placebo. Th ese fi ndings are consistent with an earlier 15-day Phase IIa cross-over study (n = 30) that also evaluated 24-hour bronchodilation with aclidinium versus placebo and tiotropium, although a larger diff erence between aclidinium and placebo for the change from baseline in FEV 1 AUC 0-24 (232 mL) was reported previously, potentially as a result of diff erences in trial design and duration (11) . Also consistent with previous fi ndings are the numerically greater improvements in nighttime bronchodilation achieved with aclidinium versus tiotropium in this study, with statistically signifi cant improvements favoring aclidinium on day 1 of treatment. Th ese day 1 fi ndings may be explained by diff erences in the pharmacokinetics of aclidinium and tiotropium, whereby aclidinium reaches steady state more quickly than tiotropium (17, 18). After 6 weeks of treatment, the 24-hour bronchodilatory effi cacy of aclidinium and tiotropium was considered to be comparable. Many patients with COPD experience earlymorning or nighttime peaks in symptom severity (5) . Although as many as 80%-90% of patients experience nighttime symptoms (19) and sleep disturbance (6), there is a lack of therapeutic options for their management. To date, a small number of studies have evaluated the efficacy of bronchodilatory therapies to improve nighttime lung function and/or sleep quality with mixed findings (2, (20) (21) (22) (23) . For example, a 6-week study in patients with stable COPD found that evening dosing of tiotropium did not result in improved nighttime bronchodilation compared with morning dosing (2). ¶ p < 0.05 for aclidinium versus tiotropium. Severity of overall early-morning and nighttime symptoms rated on a 5-point scale from 1 = 'did not experience any symptoms' to 5 = 'very severe'; individual morning symptoms rated on a 5-point scale from 0 = 'no symptoms' to 4 = 'very severe'; limitation of activity rated on a 5-point scale from 1 = 'not at all' to 5 = 'a very good deal'. ANCOVA, analysis of covariance; BID, twice daily; COPD, chronic obstructive pulmonary disease; ITT, intent-to-treat; LS, least squares; QD, once daily.
Additionally, reduced daily variation in lung function and improved nighttime oxygen saturation achieved with evening administration of tiotropium in a separate 4-week study in patients with severe COPD did not translate into improved sleep quality (21) . Conversely, four-times-daily treatment with ipratropium (a SAMA) has been shown to improve oxygen saturation and sleep quality over 4 weeks in patients with moderate-to-severe COPD (20) .
Th e impact of treatment with aclidinium on sleep quality has not been evaluated in a sleep laboratory setting; however, it has been demonstrated to improve health status and early-morning and nighttime symptoms, and to reduce the frequency of nocturnal awakenings in Phase III studies (ATTAIN and ACCORD COPD I) (24) (25) (26) (27) . In the present study, changes in COPD daily symptoms following BID dosing of aclidinium and QD dosing of tiotropium compared with placebo were assessed using the E-RS tool (14, 28) , and an additional symptoms questionnaire (currently undergoing validation), that was developed by the sponsor in the absence of a validated tool to capture the severity and impact of early-morning and nighttime symptoms.
Our results suggest that aclidinium provides statistically signifi cant improvements in early-morning and nighttime symptoms compared with placebo that were consistently numerically greater than those observed with tiotropium. Improvements in nighttime symptom severity were signifi cantly diff erent versus placebo for aclidinium only, which could suggest that the numerical advantage of aclidinium over tiotropium for greater nighttime bronchodilation may translate into statistically signifi cant changes in patient-reported outcomes. Furthermore, only aclidinium signifi cantly reduced the limitation of activity caused by COPD symptoms compared with placebo. Th is is the fi rst report of this therapeutic eff ect with a LAMA but should, along with the other COPD additional symptoms fi ndings, be interpreted with some caution given the generally mild symptoms that patients reported at baseline, the small magnitude of the reductions observed, and the as yet unvalidated state of this tool.
Th e trend towards greater symptomatic improvement with aclidinium over tiotropium observed in this study may be related to diff erences in dosing frequency. However, while a second evening dose of aclidinium may be benefi cial in terms of improving nighttime and early-morning symptoms under clinical trial conditions, the potential disadvantages of BID versus QD dosing should also be considered. Findings from an observational study have suggested that treatment adherence among patients with COPD declines with increasing dosing frequency (29) , but this appears to be a greater concern for three-and four-times-daily regimens, and there is a lack of evidence to support greater adherence to QD versus BID treatment in practice.
Furthermore, poor adherence to prescribed treatment in COPD is multifactorial: it can also be infl uenced by perceived effi cacy of treatment, side eff ects, number of concomitant medications, patient understanding, inhaler satisfaction or preference, and a number of other issues (30) (31) (32) . Due to the double-blind, double-dummy design of this study, adherence to tiotropium QD compared with aclidinium BID could not be assessed but may be of interest for future work.
Although not powered for this purpose, patients' preference for Genuair compared with HandiHaler was assessed as an additional endpoint in this study and our fi ndings were consistent with those of a previous study that reported greater preference for, greater satisfaction with, and fewer errors with, Genuair versus HandiHaler after 2 weeks' daily practice with placebo-containing devices (33).
However, in contrast with the previous study, patients inhaled both aclidinium and placebo through Genuair, and both tiotropium and placebo via HandiHaler in the present study. Patients were not asked to consider perceived effi cacy when indicating their preferred device and preference for Genuair was maintained regardless of whether it was used to deliver placebo or aclidinium.
Finally, aclidinium was generally well tolerated over 6 weeks in this study, with a similar safety profi le to tiotropium. Our fi ndings are consistent with previous Phase III studies in terms of similar incidences of AEs and serious AEs in patients treated with aclidinium or placebo (24, 25) . Th e potential for anticholinergic AEs, such as dry mouth, constipation, urinary retention, and cardiovascular events, is a risk associated with LAMAs.
Aclidinium, however, has been shown to undergo more rapid hydrolysis than tiotropium in human plasma (34, 35) and could, therefore, be considered to have the potential for fewer systemic side eff ects than tiotropium. Tiotropium has been associated with an increased risk of all-cause and cardiovascular-related mortality when administered via soft mist inhaler (36-38) but not when administered via HandiHaler (39) .
In this 6-week study, the incidence of dry mouth, constipation, and other anticholinergic AEs (<1.5% for any event) was somewhat lower than has been observed in a pooled analysis of tiotropium safety data from 26 Phase III and IV studies (39) , possibly as a result of the short trial duration and patients' previous exposure to tiotropium. Th e incidence of anticholinergic AEs was similarly low in the aclidinium treatment group, consistent with fi ndings from other Phase III studies (24, 25) .
Conclusions
Th ese fi ndings suggest that in patients with moderateto-severe COPD, aclidinium 400 μg BID provides signifi cant 24-hour bronchodilation compared with placebo from day 1 and over 6 weeks of treatment. At 6 weeks, the bronchodilatory eff ects of aclidinium and tiotropium are generally comparable. Aclidinium provides consistently numerically greater improvements in COPD symptoms, including early-morning and www.copdjournal.com nighttime symptoms, than tiotropium and is well tolerated, with a similar safety profi le. Patients in this study preferred Genuair over HandiHaler for the administration of their inhaled medications.
